Latest Industry News & Trends

Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.

Recently Added News

2/22/2024
GlaucomaMeetingNewsletter
Glaucoma 360 Showcases Innovation in Diagnosis, Management of Disease
Glaucoma 360 Showcases Innovation in Diagnosis, Management of Disease

Innovative diagnostics for glaucoma screening, staging, and management were a highlight of the Glaucoma 360 New Horizons Forum, with several physicians showcasing new approaches to visual field tes...

2/23/2024
BreakingFundingIndustryRetina
Ocular Therapeutix Announces $325 Million Private Placement, Adds Retina Specialists to Leadership Team
Ocular Therapeutix Announces $325 Million Private Placement, Adds Retina Specialists to Leadership Team

Ocular Therapeutix announced Feb. 22 that it had entered into a securities purchase agreement with institutional investors for a private placement of shares, with gross proceeds of approximately $3...

2/23/2024
BreakingCornealFundingStudy
Australian Research Team Receives $35 Million Grant to Develop Tissue-Engineered Cornea
Australian Research Team Receives $35 Million Grant to Develop Tissue-Engineered Cornea

Researchers in Australia announced Feb. 5 that they had received a $35 million grant from the national government’s Medical Research Future Fund to support the development of a tissue-engineered co...

2/23/2024
BreakingClinical TrialCornealDeals
Eversight Partners with Emmecell to Advance Corneal Cell Therapies
Eversight Partners with Emmecell to Advance Corneal Cell Therapies

Global nonprofit eye bank Eversight and Emmecell announced Feb. 20 that they would collaborate to advance cell therapies for corneal treatment. Emmecell, of Menlo Park, California, is developing EO...

2/23/2024
BreakingDiagnosticFundingOCT
Washington U. Awarded up to $20 Million Federal Grant to Create Portable OCT
Washington U. Awarded up to $20 Million Federal Grant to Create Portable OCT

Washington University in St. Louis, Missouri, announced Feb. 13 that one of its professors had been awarded a grant of up to $20 million from the Advanced Research Projects Agency for Health (ARPA-...

2/23/2024
BreakingCataractEuropeIOLMeetingSurgical
VSY Launches Enova Maestro Trifocal Toric Preloaded IOL at ESCRS Winter Meeting
VSY Launches Enova Maestro Trifocal Toric Preloaded IOL at ESCRS Winter Meeting

Germany’s VSY Biotechnology launched its Enova Maestro trifocal toric preloaded intraocular lens (IOL) at the European Society of Cataract and Refractive Surgeons (ESCRS) Winter Meeting, held Feb. ...

2/23/2024
BreakingEuropeGlaucomaMeetingSurgical
Sight Sciences Reports Launching of Omni Ergo-Series for Canaloplasty in Europe at ESCRS Winter Meeting
Sight Sciences Reports Launching of Omni Ergo-Series for Canaloplasty in Europe at ESCRS Winter Meeting

Sight Sciences announced Feb. 14 that it would launch the Ergo-Series of its Omni system for canaloplasty in Europe at the European Society of Cataract and Refractive Surgeons (ESCRS) Winter Meetin...

2/23/2024
AllergyBreakingCataractChinaPharma
Regulators in Singapore Accept NDA from AffaMed for Dextenza
Regulators in Singapore Accept NDA from AffaMed for Dextenza

Shanghai-based AffaMed Therapeutics announced Feb. 19 that the Singapore Health Sciences Authority had accepted its new drug application (NDA) for Dextenza (0.4 mg dexamethasone intracanalicular in...

2/23/2024
BreakingChinaClinical Trial
Phase II/III Trial of Innovent’s TED Candidate Meets Primary Endpoint
Phase II/III Trial of Innovent’s TED Candidate Meets Primary Endpoint

China’s Innovent Biologics announced Feb. 19 that the primary endpoint had been achieved in the company’s Phase II/III trial of IBI311, a recombinant anti-insulin-like growth factor 1 receptor (IGF...

2/22/2024
AcquisitionsDeviceNewsletterRetinaSurgical
Retinal Device Market Awaits Technological Impact of Zeiss’ DORC Acquisition
Retinal Device Market Awaits Technological Impact of Zeiss’ DORC Acquisition

Carl Zeiss Meditec’s acquisition of DORC (Dutch Ophthalmic Research Center) will change the players in the retinal surgical equipment market, but whether it will lead to any major changes in market...

2/22/2024
LaserNewsletterRefractive
Bausch + Lomb Teneo Excimer Laser Enters US Market After Drought in New Technology
Bausch + Lomb Teneo Excimer Laser Enters US Market After Drought in New Technology

A new excimer laser has entered the US refractive market for the first time in nearly two decades. Bausch + Lomb announced in January that the US FDA had approved the Teneo excimer laser platform f...

2/22/2024
AcquisitionsDealsNewsletterRetina
Sandoz Acquires Biosimilar Cimerli from Coherus for $170M Up Front
Sandoz Acquires Biosimilar Cimerli from Coherus for $170M Up Front

Swiss drugmaker Sandoz announced Jan. 22 that it had signed an agreement to acquire the US ranibizumab (Lucentis) biosimilar Cimerli from Coherus BioSciences for $170 million up front. The deal inc...

Past News Stories

2/22/2024
ChinaDry EyeIndustryNewsletter
China’s LianBio to Wind Down Operations, Sell Off Pipeline Assets
China’s LianBio to Wind Down Operations, Sell Off Pipeline Assets

Chinese biotech company LianBio announced Feb. 13 that it would wind down operations—including selling its pipeline assets, delisting its American Depositary Shares from the Nasdaq, and cutting its...

2/22/2024
NewsletterRegulation
US FDA Warns of Contamination Risk with Copycat Lumify Eye Drops
US FDA Warns of Contamination Risk with Copycat Lumify Eye Drops

The US FDA issued a warning Jan. 31 to consumers not to purchase or use South Moon, Rebright, or FivFivGo eye drops because of the potential risk of eye infection. The products are copycats that ca...

2/22/2024
IndiaNewsletterRegulation
India Orders Tougher Drug-Making Standards After Overseas Deaths
India Orders Tougher Drug-Making Standards After Overseas Deaths

Prime Minister Narendra Modi’s government has stepped up scrutiny of India’s pharmaceutical factories after being stung by a series of overseas deaths linked to Indian-made drugs. The news agency R...

2/22/2024
GlaucomaLaserNewsletterRefractiveRegulation
Select US FDA Approvals and Clearances in January 2024
Select US FDA Approvals and Clearances in January 2024

The US FDA granted two clearances through the ophthalmic device division using the 510(k) pathway in January 2024, according to the agency’s database. Meridian received clearance for three laser mo...

2/22/2024
NewsletterRegulation
CMS is Implementing Time Limit on Prior Authorization Decisions
CMS is Implementing Time Limit on Prior Authorization Decisions

The Centers for Medicare and Medicaid Services (CMS) issued a final rule on Jan. 17 that will limit the amount of time for certain payers to make prior authorization decisions. Payers will have 72 ...

2/22/2024
Clinical TrialNewsletterRegulation
Japan Eases Clinical Trial Requirements for Foreign Drugmakers in Growing Trend
Japan Eases Clinical Trial Requirements for Foreign Drugmakers in Growing Trend

Japan has removed the requirement that foreign drugmakers conduct a Phase I clinical trial in Japan before Japanese individuals participate in Phase III multiregional clinical trials (MRCT) for reg...

2/22/2024
DealsFundingGene TherapyGlaucomaNewsletterRetinaSurgical
4DMT Leads Latest Ophthalmic Fundraising with $300 Million Public Offering
4DMT Leads Latest Ophthalmic Fundraising with $300 Million Public Offering

4D Molecular Therapeutics led recent ophthalmic fundraising efforts with a $300 million upsized public offering to continue advancing its retinal gene therapy candidate. Financing announced in the ...

2/22/2024
GlaucomaMeetingNewsletterSurvey
Participation in the 2024 Glaucoma 360 Attendee Survey Hits All-Time High
Participation in the 2024 Glaucoma 360 Attendee Survey Hits All-Time High

Ophthalmologist (MD) and optometrist (OD) attendees of the 2024 Glaucoma 360 (G360) meeting demonstrated a record interest in participating in the Ninth Annual G360 Survey powered by Market Scope. ...

2/22/2024
GlaucomaMeetingNewsletterSurgical
Top Innovators Delve into Latest Concepts at G360’s New Horizons Forum
Top Innovators Delve into Latest Concepts at G360’s New Horizons Forum

Two of ophthalmology’s leading innovators headlined the New Horizons Forum at the Glaucoma 360 meeting. Sean Ianchulev, MD—arguably the most prolific ophthalmic product inventor in the US—led off t...

2/22/2024
GlaucomaMeetingNewsletterRegulation
Reimbursement Issues for Glaucoma Surgery Remain Threat, G360 Speakers Say
Reimbursement Issues for Glaucoma Surgery Remain Threat, G360 Speakers Say

Attendees of the G360 New Horizons Forum received a detailed breakdown of the battle that the ophthalmic industry collectively waged throughout 2023 to stop proposed limits to Medicare coverage for...

2/22/2024
CataractNewsletterRegulationSurgical
MAC Drops Plan to Require Visual Acuity of 20/50 or Worse for Cataract Surgery
MAC Drops Plan to Require Visual Acuity of 20/50 or Worse for Cataract Surgery

Wisconsin Physician Services (WPS), a Medicare Administrative Contractor (MAC) in the US, has abandoned a proposal to require visual acuity of 20/50 or worse for cataract surgery to be medically ne...

2/22/2024
Clinical TrialDry EyeNewsletterRetina
Clinical Trial Updates for Ophthalmic Candidates
Clinical Trial Updates for Ophthalmic Candidates

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

Want to Read the Full Article?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more